ADULT Updated: March 23, 2022

Regimen Reference Order - THOR - lurbinectedin

ARIA: LUNG - [lurbinectedin]

Planned Course: Every 21 days until progression or unacceptable toxicity

Indication for Use: Small Cell Lung Cancer

CVAD: At Provider's Discretion

Proceed with treatment if:

• ANC equal to or greater than 1.5 x $10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

- Albumin equal to or greater than 25 g/L (unless otherwise noted in medical oncologist's ARIA progress note)
 - Contact Medical Oncologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements				
	Drug	Dose	CCMB Administration Guideline	
Not Applicable				

Treatment Regimen – THOR – lurbinectedin				
Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
ondansetron	16 mg	Orally 30 minutes pre-chemotherapy		
dexamethasone	12 mg	Orally 30 minutes pre-chemotherapy		
lurbinectedin	3.2 mg/m ²	IV in normal saline 250 mL over 60 minutes		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

• CBC, serum creatinine, urea, electrolytes, liver enzymes, total bilirubin, albumin and glucose as per Physician Orders

Recommended Support Medications				
Drug	Dose	CCMB Administration Guideline		
dexamethasone	8 mg	Orally once daily on Days 2 and 3		
prochlorperazine	10 mg	Orally every 6 hours as needed for nausea and vomiting		



ADULT THOR – lurbinectedin

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- lurbinectedin has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- · Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- lurbinectedin can cause elevations in hepatic enzymes
- aprepitant should be avoided with this regimen due to risk of pancytopenia when used with lurbinectedin

